Company profile
[RE]MEDs
Real-life repurposing and repositioning of medicines
- Industry
- Biotechnology
- Employees
- 6
- Headquarters
- Paris
- Founded
- 2020
- Office locations
- 1
[RE]MEDs company summary
[RE]MEDs is a company in the Biotechnology industry, headquartered in Paris, founded in 2020. On LinkedIn the company has around 6 employees. Its listed specialties include pharmacoepidemiology, artificial intelligence, data science, health.
What technology does [RE]MEDs use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About [RE]MEDs
The objective of [RE]MEDs is to contribute to the discovery of new medicinal applications to meet significant unmet medical needs, leveraging the most sophisticated data science technology. To achieve this, we have developed an AI-powered methodology and corresponding technology for in-silico studies of medicinal effects, utilizing extensive electronic databases of medical, hospital, and administrative health records. Our current focus is on autoimmune disorders. Founded in 2020 by research entrepreneurs with internationally renowned scientific reputations and a track record of highly successful business ventures, [RE]MEDs was instrumental in evaluating drugs during the pandemic and researching solutions using existing data. The company currently employs a diverse team of about a dozen staff, including university professors in pharmacoepidemiology and biostatistics, PhD-level Data/AI scientists, senior programmers, and engineers. This internationally-based team has expertise in hundreds of electronic health and medical databases worldwide. The team is headed by Billy Amzal, PhD, CEO, a biomathematician (École Polytechnique, France) with extensive experience in the pharmaceutical industry and related consulting firms. The Chief Scientific Officer is Prof. Yola Moride, former President of the International Society of PharmacoEpidemiology (ISPE), research professor at Rutgers University (USA), and founder of an international consultancy. The founder and Board President is Prof. Lucien Abenhaim, who previously worked at the WHO and founded several highly successful international Medtech companies. [RE]MEDs’ business model encompasses proprietary research and collaborative research with industry, NGOs, or academia. It is backed by the BPI/Deeptech program (France). [RE]MEDs is committed to upholding ethics in medicine and pharmaceutical research, environmental protection, occupational health, and is an equal opportunity employer.
Specialties
Where is [RE]MEDs located?
[RE]MEDs lists 1 location.
Compare companies similar to [RE]MEDs
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
[RE]MEDs re-meds.com | Biotechnology | 6 | 2020 | Paris |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about [RE]MEDs
What does [RE]MEDs do?
The objective of [RE]MEDs is to contribute to the discovery of new medicinal applications to meet significant unmet medical needs, leveraging the most sophisticated data science technology. To achieve this, we have developed an AI-powered methodology and corresponding technology for in-silico studies of medicinal effects, utilizing extensive electronic databases of medical, hospital, and administrative health records. Our current focus is on autoimmune disorders. Founded in 2020 by research entrepreneurs with internationally renowned scientific reputations and a track record of highly successful business ventures, [RE]MEDs was instrumental in evaluating drugs during the pandemic and researching solutions using existing data. The company currently employs a diverse team of about a dozen staff, including university professors in pharmacoepidemiology and biostatistics, PhD-level Data/AI scientists, senior programmers, and engineers. This internationally-based team has expertise in hundreds of electronic health and medical databases worldwide. The team is headed by Billy Amzal, PhD, CEO, a biomathematician (École Polytechnique, France) with extensive experience in the pharmaceutical industry and related consulting firms. The Chief Scientific Officer is Prof. Yola Moride, former President of the International Society of PharmacoEpidemiology (ISPE), research professor at Rutgers University (USA), and founder of an international consultancy. The founder and Board President is Prof. Lucien Abenhaim, who previously worked at the WHO and founded several highly successful international Medtech companies. [RE]MEDs’ business model encompasses proprietary research and collaborative research with industry, NGOs, or academia. It is backed by the BPI/Deeptech program (France). [RE]MEDs is committed to upholding ethics in medicine and pharmaceutical research, environmental protection, occupational health, and is an equal opportunity employer.
How many employees does [RE]MEDs have?
[RE]MEDs has around 6 employees on LinkedIn.
Where is [RE]MEDs headquartered?
[RE]MEDs is headquartered in Paris.
When was [RE]MEDs founded?
[RE]MEDs was founded in 2020.
Build a lead list from companies like [RE]MEDs
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.